We use cookies and other tracking technologies to improve your browsing experience on our website, to show you personalized ...

Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid ...

Bio-Thera Solutions and SteinCares have signed a new agreement to commercialize a proposed biosimilar of dupilumab across ...

This new agreement marks the fourth product in the partnership and introduces a potential cost-effective alternative to one ...

Also, Dupilumab, in collaboration with SNY, is prescribed for pediatric asthma [PA], bullous pemphigoid [BP], and chronic urticaria [CU]. REGN is also developing Eylea HD [aflibercept] for a new ...

Between dupilumab and benralizumab, researchers found a significantly reduced rate of asthma exacerbations in the dupilumab group (1.07 per year vs. 1.47 per year; rate ratio, 0.73; 95% CI, 0.63-0 ...

Dupilumab (Dupixent), a medicine that you get as a shot, is the first new treatment for CSU in the U.S. in over a decade. It’s already used to treat different inflammation conditions in the U.S ...

Patients with atopic dermatitis (AD) treated with dupilumab may face a slightly elevated risk of developing psoriasis, with new study data showing a cumulative 3-year incidence of 2.86% compared ...

In a post-hoc analysis, dupilumab improved symptoms of atopic dermatitis (AD) in young children ages 6 months to 5 years. Youngsters with associated comorbidities such as asthma, allergic rhinitis ...

She will lead a multicenter controlled trial of 76 children with alopecia affecting at least 30% of the scalp, who will be randomized 2:1 (dupilumab:placebo) for 48 weeks, followed by 48 weeks of ...

Bio-Thera Solutions & SteinCares expand partnership to commercialize biosimilars to treat inflammatory diseases across Latin America: Guangzhou, China Thursday, June 26, 2025, 12: ...